Evidence map›Paper›PMID 42646065›Full record

ReviewJournal of xenobiotics2026

Beyond the Status Quo: Particulate Matter Standards in Oral Dosage Forms.

Gourav Pandey, Hitesh Chavda

Abstract readReview
In one paragraph

Review in Journal of xenobiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gourav PandeyTakeda Pharmaceuticals, Boston, MA 01801, USA.ORCID 0009-0003-7755-8707
Hitesh ChavdaIndependent Researcher, Gandhinagar 382010, India.ORCID 0000-0001-8821-7578

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Particulate contamination in oral dosage forms poses significant challenges to product integrity and patient trust, yet these formulations lack the well-defined regulatory limits established for injectables. This review comprehensively analyses existing literature, regulatory guidelines, and analytical techniques to identify primary contamination sources, assess regulatory gaps, and propose science-based mitigation strategies. Key contamination vectors include raw materials, manufacturing equipment, facilities, packaging, personnel activities, utilities, processing aids, cleaning residues, and process design deficiencies. While solid oral dosage forms can encapsulate particulates, liquid formulations present a heightened ingestion risk. To combat these vulnerabilities, advanced analytical techniques-such as Fourier transform infrared spectroscopy, Raman spectroscopy, scanning electron microscopy with energy-dispersive X-ray spectroscopy, and X-ray fluorescence-are evaluated alongside emerging artificial intelligence-driven detection and real-time monitoring systems. Because current regulations inadequately address particulate matter in oral dosage forms, this paper introduces a structured decision pathway model to enhance contamination management. Ultimately, regulatory harmonization is essential for patient safety, and future research must focus on refining detection methodologies, risk-based strategies and establishing scientifically justified particulate thresholds.

Indexed as

analytical spectroscopydecision pathway modeloral dosage formsparticulate contaminationparticulate matterregulatory harmonizationregulatory standards

Identifiers

PMID42646065
PMCPMC13514903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.